Building a world where
tomorrow is another day!

Home
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • Apr 28, 2025 Notice of Discontinuation of Development of CTX-177 (ONO-7018) pdf (289KB)
  • Apr 25, 2025 Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025 pdf (229KB)
  • Apr 24, 2025 Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025 pdf (276KB)
  • Apr 11, 2025 For 2nd quarter FY8 2025 Financial Results Presentation pdf (1,132KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Investor Relations
Investor Relations

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

People

People

Contact

Contact

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box